We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Osiris Therapeutics, Inc. (NASDAQGM: OSIR) to Smith & Nephew plc. Under the terms of the transaction, Osiris shareholders will receive $19.00 for each share of Osiris stock they own.
The Osiris merger investigation concerns whether the Board of Osiris breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Smith & Nephew is underpaying for Osiris shares, thus unlawfully harming Osiris shareholders.
To receive more information, please fill out the form.